Relationship between HLA-DRB1 Allele Polymorphisms and Familial Aggregations of Hepatocellular Carcinoma

Abstract

Objective We explored the relationship between HLA-DRB1 allele polymorphisms and familial aggregation of hepatocellular carcinoma (fhcc).Methods Polymerase chain reaction sequence-specific primers were used to determine HLA-DRB1 genotypes for 130 members of families with 2 or more liver cancer patients and for 130 members of families without any diagnosed cancers. The genotype profiles were then compared to explore the relationship between HLA-DRB1 gene polymorphism and fhcc.Result Of 11 selected alleles, the frequencies of DRB1*11 and DRB1*12 were significantly lower in the fhcc group than in no-cancer group (p < 0.05; odds ratio: 0.286; 95% confidence interval: 0.091 to 0.901; and odds ratio: 0.493; 95% confidence interval: 0.292 to 0.893). Differences in the frequencies of the other 9 alleles were not statistically significant in the two groups (p > 0.05). ConclusionsOur research suggests that if genetic factors play a role in fhcc, the deficiency in the DRB1*11 and DRB1*12 alleles might be the risk factor at work in Guangxi Zhuang Autonomous Region, P.R.C.

Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma

“…Moreover, familial aggregation and co-aggregation of HCC have indicated that genetic factors play a major role in the development of HCC. Previous molecular studies have reported that genetic factors, such as the genes coding for human leukocyte antigen (HLA)-DRB1, FasL, epidermal growth factor, human serum antigen-miR-1269, cyclooxygenase-2, and methylene tetrahydrofolate reductase, play an essential role in HCC susceptibility (Shen et al, 2015;Wang et al, 2015;Xiong et al, 2015;Zhang et al, 2015;Khalifa et al, 2016;Ma et al, 2016).…”

Carriage of HLA-DRB1*11 and 1*12 alleles and risk factors in patients with breast cancer in Burkina Faso

“…Using the BioDrop µLITE, DNA was quantified and purity was verified. Amplification of HLA-DRB1*11 and HLA-DRB1*12 alleles was performed using the primers described by Ma et al [ 27 ], with a slightly adapted amplification program. This was a multiplex PCR targeting both alleles simultaneously, performed with the GeneAmp PCR System 9700 (Applied Biosystem, USA).…”

HLA Class II Allele Polymorphisms and the Clinical Outcomes of HBV Infection

“…Analysis still identified HLA-DRB 1 *12:02 as the top susceptible HLA allele associated with acute-on-chronic liver failure (ACLF) [35]. A large number of studies have been conducted to identify HLA-DRB1 genetic variants associated with HCC risk and clinical outcomes, but many of the findings in these studies are inconsistent and inconclusive [36][37][38]. A meta-analysis by Lin et al reported an ethnicity-dependent association between specific HLA-DRB1 alleles and HCC risk, DRB 1 *07 and DRB 1 *12 were significantly associated with the risk of HCC in the whole populations, and DRB 1 *15 allele significantly increased the risk of hepatocellular carcinoma only in Asians [36].…”

“…One research by Ma et al suggests that if genetic factors play a role in familial aggregation of hepatocellular carcinoma, the deficiency in the DRB 1 *11 and DRB 1 *12 alleles might be the risk factor at work in the Guangxi Zhuang Autonomous Region, P.R.C. [37]. Another meta-analysis by Liu et al reported that HLA-DRB 1 *01 and 11 alleles were protective factors, while HLA-DRB 1 *12 and 14 alleles were risk factors for HCC development [38].…”